X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to support the Biocon for the commercialization of ACTIBLOK IPR 25 (metoprolol succinate). It is an approved product indicated for the treatment of hypertension and angina pectoris.
Lead Product(s): Metoprolol Succinate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ACTIBLOK IPR 25
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eris Pharmaceuticals
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration March 13, 2024
Details:
The partnership seeks to enhance the commercialization efforts of Ogivri (trastuzumab), an FDA-approved biosimilar product utilized in the treatment of patients diagnosed with breast cancer or metastatic stomach cancer.
Lead Product(s): Trastuzumab
Therapeutic Area: Oncology Product Name: Ogivri
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sandoz B2B
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 10, 2024
Details:
Through the divestment, Eris gains Biocon's Dermatology and Nephrology branded formulations business units in India that mostly comprised of its legacy small molecules’ brands, including Advacan (everolimus), an anti-cancer medicine.
Lead Product(s): Everolimus
Therapeutic Area: Oncology Product Name: Advacan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eris Lifesciences
Deal Size: $43.8 million Upfront Cash: Undisclosed
Deal Type: Divestment November 09, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
